HC Wainwright & Co. Maintains Buy on Sana Biotechnology, Lowers Price Target to $11
HC Wainwright & Co. Maintains Buy on Sana Biotechnology, Lowers Price Target to $11
HC Wainwright & Co.維持對Sana生物技術的買入評級,將目標價調降至11美元。
HC Wainwright & Co. analyst Emily Bodnar maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $12 to $11.
HC Wainwright & Co.分析師Emily Bodnar維持對Sana Biotechnology (NASDAQ:SANA)的買入評級,並將目標股價從12美元下調至11美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。